CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 155 enrolled
Drug / intervention
GnRHant - Ganirelix acetate +2 moredrug
Likely dose
GnRHant - Ganirelix acetate 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00608062
NCT00608062N/ACompleted

Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency

University of Colorado, Denver·interventional·Posted Feb 6, 2008·Updated Dec 24, 2020

In Brief

A clinical study evaluating GnRHant - Ganirelix acetate, Transdermal estradiol patch, and 1 other intervention for Arterial Stiffening and 2 related conditions. Completed, enrolled 155 participants across 1 site.

Detailed Summary

The purpose of this study is to find out why women's arteries stiffen as they go through menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with the loss of estrogen because of "oxidative stress," the production of molecules that can damage cells and tissues in the body, and because the arteries lose their ability to expand, or dilate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2008
Enrollment StartMar 1, 2007
Primary CompletionOct 25, 2012
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 18.4 years ago

Interventions

GnRHant - Ganirelix acetatedrug

1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Transdermal estradiol patchdrug

0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Transdermal placebo patchdrug

Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)